Skip to main content

Investor RelationsWealth Management:  CA  |  UK  |  AU

Menu

BEIJING | CHINA

Partnering to deliver
global solutions
tailored to your unique needs

Transactions

Our corporate finance solutions are tailored to our clients’ strategic goals and delivered based on in depth expertise across a wide range of sectors globally. We have a strong track record, participating in 713 transactions and raising C$86.1 billion on behalf of our clients in fiscal 20211.2.

Filter our transactions* using the categories below:

OrthogenRx, Inc.
Pending Completion

OrthogenRx, Inc.

Financial Advisor (Sell side)
HEALTHCARE M&A ADVISORY US
View transaction detail
Panbela Therapeutics
June 2022

Panbela Therapeutics

Exclusive Financial Advisor (Buy side)
HEALTHCARE M&A ADVISORY US
View transaction detail
Arcellx, Inc.
US$112m
June 2022

Arcellx, Inc.

Joint Bookrunner (Follow-On)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
KemPharm, Inc.
May 2022

KemPharm, Inc.

Financial Advisor (Buy side)
HEALTHCARE M&A ADVISORY US DENMARK
View transaction detail
RiteGene Technologies
April 2022

RiteGene Technologies

Exclusive Financial Advisor (Sell side)
HEALTHCARE CANNABIS M&A ADVISORY US
View transaction detail
Selecta Biosciences
US$38.7m
April 2022

Selecta Biosciences

Co-Manager (Follow-on)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
Inari Medical
US$186m
March 2022

Inari Medical

Co-Manager (Follow-on Offering)
HEALTHCARE EQUITY CAPITAL MARKETS US
Aytu Biopharma
US$7.5m
March 2022

Aytu Biopharma

Sole Bookrunner (Follow-on Offering)
HEALTHCARE EQUITY CAPITAL MARKETS US
Amryt Pharma plc
$125m
February 2022

Amryt Pharma plc

Lead Financial Advisor
HEALTHCARE DEBT ADVISORY & RESTRUCTURING IRELAND
View transaction detail
Intra-Cellular Therapies
US$460m
January 2022

Intra-Cellular Therapies

Co-Manager (Follow-on Offering)
HEALTHCARE EQUITY CAPITAL MARKETS US
ImmunoGen Inc.
US$257m
December 2021

ImmunoGen Inc.

Lead Manager (Follow-on)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
Privia Health Group, Inc.
US$174m
November 2021

Privia Health Group, Inc.

Co-Manager (Follow-on)
HEALTHCARE EQUITY CAPITAL MARKETS US
View transaction detail
  1. Company information as of March 31, 2022
  2. Transactions valued above C$1.5 million

* Transactions displayed here include transactions of Canaccord Genuity and its predecessors. The logos used in the tombstones represent Canaccord Genuity’s clients unless otherwise specified in the transaction description

How can we help?

If you would like to find out more about Canaccord Genuity or any of our services, please get in touch.